마우스 및 인간 눈물샘 오가노이드의 확립, 유지, 분화, 유전자 조작 및 이식

Executive Industry Relevance

Lacrimal gland organoid systems enable mechanistic interrogation of glandular homeostasis and genetic function in a controlled, disease-relevant context. This platform supports predictive confidence for target validation and functional genomics, bridging early discovery with translational research in ocular surface disorders. The ability to manipulate, differentiate, and transplant both mouse and human organoids positions this workflow as a reusable asset for portfolio-wide biological de-risking.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct testing of gene function in lacrimal gland epithelial biology.
• Supports mechanistic de-risking by isolating genetic and environmental variables.
• Facilitates functional target validation through genetic manipulation and phenotypic readouts.
• Provides a platform for hypothesis-driven interrogation of glandular pathways.

Screening & Assay Development

• Delivers standardized, reproducible organoid cultures for quantitative secretion assays.
• Enables assay development using neurotransmitter-induced tear release as a functional endpoint.
• Supports scalability and platform reuse for compound screening in disease-relevant systems.
• Allows for robust comparison of genetic and pharmacological perturbations.

Translational & Preclinical Research

• Aligns in vitro findings with in vivo regenerative potential via orthotopic transplantation.
• Enables continuity from genetic discovery to preclinical validation in humanized models.
• Supports risk-adjusted advancement decisions for regenerative medicine programs.
• Provides a bridge between molecular mechanism and tissue-level function.

Pipeline & Workflow Integration

This organoid workflow integrates from early discovery through lead identification and preclinical validation, supporting both mechanistic studies and translational research in ocular biology.

• Discovery Biology: Facilitates hypothesis testing and pathway clarification in lacrimal gland homeostasis.
• Screening: Provides reproducible, quantitative secretion assays for functional screening.
• Analytics: Enables imaging and quantification of neurotransmitter-induced tear release and genetic outcomes.
• Translational Research: Connects in vitro genetic manipulation to in vivo regenerative assessment via transplantation.
• Enterprise Reuse: Establishes a reusable organoid platform for diverse genetic and pharmacological studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
• Operational Value: Standardizes workflows for reproducibility and scalability across teams.
• Strategic Value: Improves go/no-go decisions and capital efficiency by enabling early biological de-risking.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of ocular and regenerative programs.

Implementation Considerations

• Requires expertise in organoid culture, genetic manipulation, and quantitative imaging.
• Demands access to electroporation equipment, time-lapse microscopy, and molecular biology tools.
• Necessitates cross-team standardization for reproducibility in genetic and functional assays.
• Adaptation may be needed for different tissue sources or disease models.
• Careful control of digestion and handling steps is critical to maintain organoid viability and establishment rates.

Biopharma FAQs